Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC). (2025). SKIN The Journal of Cutaneous Medicine, 9(6), s689. https://doi.org/10.25251/cpgrax68